October, 2024
October 2024
M T W T F S S
 123456
78910111213
14151617181920
21222324252627
28293031  
Bispecific antibodies for cancer therapy
Sep 24, 2024, 18:03

Bispecific antibodies for cancer therapy

“The present and future of bispecific antibodies for cancer therapy”

Authors: Christian Klein, Ulrich Brinkmann, Janice Reichert and Roland Kontermann

Bispecific antibodies for cancer therapy

“Bispecific antibodies (bsAbs) allow therapeutic applications that cannot be achieved using conventional antibodies. There are 14 bsAbs approved: 11 for cancer and 3 for non-oncology indications.

This review summarizes this very active field, including bsAb signaling pathway modulators, tumor-targeted receptor agonists, ADC, bispecific T cell, natural killer cell and checkpoint inhibitors.”

 

Bispecific antibodies for cancer therapy

Source: Jean-Charles Soria/LinkedIn

Jean-Charles Soria serves as Amgen’s senior vice president of Oncology within Global Development. He is a medical oncologist and a professor of medicine at Paris-Saclay University. From 2017 to 2019, he was the senior vice president of Research and Development in Oncology at AstraZeneca. Additionally, Soria has authored or co-authored over 670 articles in leading international journals and has been recognized as one of the world’s most influential research scientists.